Pioneering Medicines

Exciting news as Flagship and Pfizer partner to create transformational medicines. Pioneering Medicines, in collaboration with Pfizer’s R&D leadership, will lead the exploration process and be responsible for driving program development. More here: https://bit.ly/44Bb4ZK

Congratulations to Flagship Pioneering's expanded leadership team and to Pioneering Medicines President Paul Biondi on his promotion to General Partner. Under Paul's leadership, our 100+ person team of drug discovery and development experts are working to make #BiggerLeaps for patients with a new innovation supply chain model that will dramatically alter the speed and reliability of innovations coming to market. #WeAreFlagship 

“Partnerships have long been core to Flagship’s strategy for maximizing value creation and the impact of our companies,” shares Flagship Founder & CEO Noubar Afeyan. Learn more about Flagship Pioneering's capital raise and how it will fuel the work of Pioneering Medicines to accelerate the creation and development of novel therapeutics for patients including through our pioneering partnerships. #BiggerLeaps

Welcome Janeen Doyle!

“Since launching this unique alliance between Flagship and Pfizer we have been working together to rapidly build out a portfolio of exploration programs. This agreement will enable ProFound Therapeutics to explore how its pioneering platform can tackle unmet need in obesity. It is an exciting milestone for the partnership and the pipeline of programs we are developing to deliver potential new and transformational medicines,” shares Paul Biondi, President of Pioneering Medicines & Flagship Executive Partner. Read more about today’s announcement ⬇ and hear more about our partnership with Pfizer in this fireside chat between Paul and Charlotte Allerton, Head of Discovery and Early Development at Pfizer: https://bit.ly/4edx9Tn

"Working across disease areas from cystic fibrosis to rare diseases to oncology is unique for a data science bioinformatics person like me and its very attractive for someone in the analytics space who doesn’t want to be focused on program, one modality, one disease area.” ➡ Read more about Iulian Pruteanu-Malinici, Director of Bioinformatics at Pioneering Medicines, including how he’s helping advance our broad portfolio in our 🌟new series🌟 spotlighting team members across Pioneering Medicines

"Working with the amazing and talented scientists across Pioneering Medicines and Flagship Pioneering is one of the best parts of my job as we try to develop and create a novel, best-in-class medicine and get that to patients as quickly as possible." ➡ Meet Caroline Woo, Senior Director of Research at Pioneering Medicines in our new 🌟employee spotlight series🌟 and learn about her role helping advance potential breakthrough treatments for people with cystic fibrosis.

A great Day of Service spent with colleagues across Flagship and our companies volunteering with non-profit organizations working tirelessly to make a difference for communities throughout Greater Boston. #WeAreFlagship #FlagshipImpact

Couldn’t agree with you more Uli Stilz that partnership takes hard work and commitment from the earliest days and how important it is to celebrate milestones along the way! The Pioneering Medicines team looks forward to our work ahead together with Novo Nordisk and Lovisa Afzelius and her team at Metaphore Biotechnologies.

Flagship-founded companies joined other leaders in #cellandgenetherapy at the American Society of Gene & Cell Therapy's Annual Meeting, sharing strides in the development of their respective bioplatform technologies and progress toward potentially transformative medicines. Read the full summary and highlights below: https://lnkd.in/emmmbgbN 🔷 Ring Therapeutics shared data in nonhuman primates showing the ability to redose genetic medicines using their vectors based on a little-known class of viruses called anelloviruses.  🔷 Tessera Therapeutics displayed curative results in humanized mouse models using its Gene Writers and proprietary lipid nanoparticles to restore normal hemoglobin production in hematopoietic stem cells in the bone marrow without chemotherapy or mobilization for the treatment of #sicklecelldisease.  🔷 Alltrna demonstrated robust ability to readthrough premature stop codons in mouse models, promising preclinical results that suggest their engineered tRNAs could offer a versatile approach to rescue protein production in rare and ulta-rare diseases caused by nonsense mutations, known as stop codon disease.  🔷 Omega Therapeutics showed preclinical data highlighting their ability to program epigenetic controllers to upregulate gene expression for a variety of genes types and cell conditions, providing effects that last weeks to months after a single dose.  🔷 Sana Biotechnology, Inc. displayed data showing a promising safety profile for their in vivo CAR T therapy, suggesting its potential to offer comparable efficacy and genomic safety as established treatments.